TY - JOUR
T1 - cGMP signaling in cardiovascular diseases
T2 - Linking genotype and phenotype
AU - Dang, Tan An
AU - Schunkert, Heribert
AU - Kessler, Thorsten
N1 - Publisher Copyright:
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Cyclic guanosine 3',5'-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.
AB - Cyclic guanosine 3',5'-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.
KW - CGMP
KW - Cardiovascular diseases
KW - Coronary artery disease
KW - Genetics
KW - Genome-wide association studies
KW - Myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85085855066&partnerID=8YFLogxK
U2 - 10.1097/FJC.0000000000000744
DO - 10.1097/FJC.0000000000000744
M3 - Review article
C2 - 32487847
AN - SCOPUS:85085855066
SN - 0160-2446
VL - 75
SP - 516
EP - 525
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 6
ER -